Form 4 for STLN Starling Oncology, Inc.
Accepted 2023-12-28 00:00:00 ET · period of report 2023-12-26 · accession 0001628280-23-042815 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-28 | 2023-12-26 | STLN | O'Meara Maeve | Dir | A - Grant | $0.00 | +50.0K | 109.1K | +85% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2023-12-26 | A | A | 50,000 | $0.00 | 109,104 | D | — | — | (F1) Represents restricted stock units that vest in full on TOI, Inc. 2024 annual shareholder meeting date, subject to continued service with the Company through such vesting date. |